Cynata Therapeutics (ASX:CYP)
ASX announcement history & article coverage
Transparent by design.
Announcments by Cynata Therapeutics (ASX:CYP) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Appendix 4E & Preliminary Final Report
Proposed issue of securities - CYP
June 2026 Quarterly Activity Report & Appendix 4C
Cynata Therapeutics reports mixed clinical trial results, implements major cost cuts, and secures R&D loan
Notification of cessation of securities - CYP
Final Director's Interest Notice
Board, Management Changes, Expenditure Reductions, RDTI Loan
Cynata Therapeutics cuts all staff including CEO, secures R&D loan, extends cash runway beyond 2027
Ceasing to be a substantial holder
Change in substantial holding
Becoming a substantial holder
Ceasing to be a substantial holder
Investor Webinar
Reinstatement to Official Quotation
Cynata Therapeutics trading suspension lifted after clinical trial results announcements
CYP-004 Osteoarthritis Trial Results
Cynata's Phase 3 CYP-004 Osteoarthritis Trial Shows No Significant Benefit Over Placebo
CYP-001 GvHD Trial Primary Evaluation Results
Cynata Therapeutics terminates Phase 2 CYP-001 trial after no significant efficacy in graft versus host disease
Suspension from Quotation
Cynata Therapeutics requests ASX suspension pending clinical trial results
Trading Halt